Answers are grounded in this paper and cite their sources.
Advanced donor age is an established determinant of worse outcomes in allogeneic hematopoietic cell transplantation (HCT) using methotrexate/calcineurin inhibitor (CNI)-based graft-versus-host disease (GVHD) prophylaxis. But recent analyses of overlapping populations receiving post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis have reported different estimates of the magnitude and donor-type dependence of this association. Using a Center for International Blood and Marrow Transplant Research (CIBMTR) cohort, we analyzed 5,873 patients with acute leukemia or myelodysplastic syndrome undergoing first allogeneic HCT using matched unrelated (MUD) or haploidentical donors with PTCy. Outcomes included overall survival (OS), GVHD-free/relapse-free survival (GRFS), relapse, non-relapse mortality (NRM), acute GVHD, and chronic GVHD. We applied a hybrid analytical framework combining machine learning-based survival modeling (XGBoost) and multivariable Cox regression using generalized propensity score weighting. Considering MUD and haploidentical donors, each 10-year increase in donor age was associated with inferior OS (HR, 1.076; 95%CI, 1.030-1.124; p=0.001) and GRFS (HR, 1.098; 95%CI, 1.060-1.138; p<0.001) and higher risks of NRM and acute and chronic GVHD. Donor age was not significantly associated with relapse, and donor age-by-donor type interactions were not statistically significant. Model-estimated 24-month OS decreased from 63.3% at donor age 25 to 59.4% at age 45, and GRFS from 43.8% to 37.1%. Our findings provide an alternative characterization of donor-age associations in PTCy-based HCT and suggest that increasing donor age remains associated with adverse transplant outcomes without clear evidence of different effects between MUD and haploidentical donors.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: